bezafibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists 362 41859-67-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bezafibrate
  • befizal
  • benzofibrate
  • difaterol
  • bezatol
  • bezalip
An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
  • Molecular weight: 361.82
  • Formula: C19H20ClNO4
  • CLOGP: 3.70
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 75.63
  • ALOGS: -5.37
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 23.69 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.108 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 4.375 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 7.870 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.844 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 4.920 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 6.830 % High 1
herg hERG pIC50 4.687 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.198 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.112 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 3.140 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK 19
kinase-selectivity-class ACVR2B,AXL,BRAF,EIF2AK3,GRK2 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.342 High 1
mh-clint Mouse hepatocyte intrinsic clearance 13.868 High 1
mppb Mouse plasma protein binding (% unbound) 10.730 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.455 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 5.150 % High 1
rh-clint Rat hepatocyte intrinsic clearance 5.585 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 82.150 % High 1
rppb Rat plasma protein binding (% unbound) 3.340 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 961.612 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1978 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diverticular perforation 78.82 24.28 18 1995 3754 90622680
Vascular stent stenosis 68.25 24.28 12 2001 664 90625770
Coronary artery thrombosis 68.18 24.28 13 2000 1129 90625305
Carotid arteriosclerosis 60.99 24.28 12 2001 1228 90625206
Arterial stenosis 60.60 24.28 11 2002 730 90625704
Helicobacter gastritis 57.21 24.28 12 2001 1688 90624746
Cor pulmonale acute 45.56 24.28 8 2005 439 90625995
Hepatic cyst 41.10 24.28 12 2001 6556 90619878
Coronary artery stenosis 39.13 24.28 11 2002 5255 90621179
Cardiorenal syndrome 38.28 24.28 8 2005 1104 90625330
Acute coronary syndrome 35.21 24.28 12 2001 10801 90615633
Coronary artery occlusion 33.86 24.28 11 2002 8543 90617891
Glycosylated haemoglobin decreased 30.21 24.28 6 2007 643 90625791
Thalamus haemorrhage 29.32 24.28 6 2007 747 90625687
Hallucinations, mixed 29.23 24.28 9 2004 5880 90620554
Hepatic function abnormal 29.00 24.28 16 1997 46272 90580162
Product prescribing error 26.27 24.28 13 2000 30132 90596302
Obstruction gastric 26.26 24.28 6 2007 1250 90625184
Blood alkaline phosphatase abnormal 25.75 24.28 6 2007 1362 90625072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis acute 56.28 22.51 30 2264 33534 42585507
Hypertriglyceridaemia 38.67 22.51 16 2278 10110 42608931
Hepatic function abnormal 30.65 22.51 24 2270 51543 42567498
Primary mediastinal large B-cell lymphoma stage IV 30.04 22.51 4 2290 11 42619030
Blood creatine phosphokinase increased 27.65 22.51 22 2272 48316 42570725
Periorbital haemorrhage 27.65 22.51 5 2289 131 42618910
Cerebral infarction 26.45 22.51 18 2276 31151 42587890
Renal impairment 26.33 22.51 31 2263 110197 42508844
Brain stem ischaemia 26.11 22.51 5 2289 180 42618861
Diabetes mellitus 25.44 22.51 23 2271 60064 42558977
Interstitial lung disease 23.78 22.51 25 2269 78437 42540604
Histology abnormal 22.93 22.51 5 2289 345 42618696

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diverticular perforation 58.66 19.96 18 4478 6344 110578459
Pancreatitis acute 57.99 19.96 34 4462 60240 110524563
Hepatic function abnormal 52.65 19.96 37 4459 89258 110495545
Vascular stent stenosis 51.23 19.96 12 4484 1517 110583286
Hypertriglyceridaemia 49.02 19.96 20 4476 16134 110568669
Coronary artery thrombosis 46.83 19.96 13 4483 3231 110581572
Arterial stenosis 45.39 19.96 11 4485 1608 110583195
Helicobacter gastritis 44.83 19.96 12 4484 2604 110582199
Carotid arteriosclerosis 42.98 19.96 12 4484 3045 110581758
Acute kidney injury 42.46 19.96 85 4411 635345 109949458
Renal impairment 40.72 19.96 44 4452 188401 110396402
Rhabdomyolysis 38.85 19.96 35 4461 120366 110464437
Blood creatine phosphokinase increased 37.85 19.96 28 4468 73049 110511754
Cor pulmonale acute 36.49 19.96 8 4488 752 110584051
Interstitial lung disease 32.69 19.96 34 4462 139300 110445503
Hepatic cyst 31.96 19.96 12 4484 7771 110577032
Primary mediastinal large B-cell lymphoma stage IV 31.16 19.96 4 4492 11 110584792
Cerebral infarction 29.43 19.96 21 4475 51817 110532986
Cardiorenal syndrome 29.13 19.96 8 4488 1910 110582893
Acute coronary syndrome 27.52 19.96 15 4481 23097 110561706
Coronary artery occlusion 26.78 19.96 13 4483 15759 110569044
Diabetes mellitus 26.50 19.96 26 4470 99355 110485448
Coronary artery stenosis 25.37 19.96 12 4484 13746 110571057
Glycosylated haemoglobin decreased 24.83 19.96 6 4490 866 110583937
Hyperuricaemia 24.74 19.96 12 4484 14519 110570284
Periorbital haemorrhage 24.62 19.96 5 4491 325 110584478
Blood triglycerides increased 24.33 19.96 14 4482 23912 110560891
Erythema multiforme 23.21 19.96 13 4483 21084 110563719
Blood alkaline phosphatase abnormal 22.51 19.96 6 4490 1281 110583522
Acute myocardial infarction 22.49 19.96 22 4474 83755 110501048
Hallucinations, mixed 20.50 19.96 9 4487 8684 110576119
Thrombotic cerebral infarction 20.25 19.96 5 4491 789 110584014
Thalamus haemorrhage 20 19.96 6 4490 1958 110582845

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB02 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35679 antilipemic drug
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:176497 geroprotector

Related Drugs by ATC class:

C10AB Fibrates 11 drugs
aluminium clofibratecholine fenofibrateciprofibrateclofibrateclofibrideetofibratefenofibrategemfibrozilpemafibrateronifibratesimfibrate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
End stage renal disease contraindication 46177005 DOID:784




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.71 acidic
pKa2 12.78 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 4.30 IUPHAR IUPHAR
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Lipoprotein lipase Enzyme WOMBAT-PK
Fatty acid-binding protein, intestinal Cytosolic other Ki 4.48 CHEMBL
Peroxisome proliferator-activated receptor delta Nuclear hormone receptor EC50 4.45 CHEMBL
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor EC50 4.18 WOMBAT-PK
Fatty acid-binding protein, liver Cytosolic other Ki 4.35 CHEMBL

External reference:

IDSource
N0000166742 NUI
D01366 KEGG_DRUG
1525 RXNORM
C0005330 UMLSCUI
CHEBI:47612 CHEBI
PEM PDB_CHEM_ID
CHEMBL264374 ChEMBL_ID
DB01393 DRUGBANK_ID
D001629 MESH_DESCRIPTOR_UI
39042 PUBCHEM_CID
2668 IUPHAR_LIGAND_ID
3968 INN_ID
Y9449Q51XH UNII
319937007 SNOMEDCT_US
396025003 SNOMEDCT_US
003937 NDDF
Y9449Q51XH INXIGHT DRUGS

Pharmaceutical products:

None